Which may influence the course of rheumatoid arthritis?

Which may influence the course of rheumatoid arthritis?

• A. Antiviral
• B. Decongestant
• C. DMARDs
• D. Emetic

Answer: (C)

DMARDs are the class that can influence the course of rheumatoid arthritis by actually slowing or halting the underlying inflammatory process that drives joint damage. They target the immune mechanisms that cause synovitis and erosion, so using them can reduce radiographic progression, preserve joint function, and improve long-term outcomes. Conventional options like methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide, as well as biologic agents that inhibit TNF or other inflammatory pathways, illustrate how this class changes the disease trajectory rather than just masking symptoms. Other options don’t alter the disease course. Antivirals treat viral infections and have no direct effect on the autoimmune inflammation of RA. Decongestants are used for nasal symptoms and do not impact the inflammatory process in joints. Emetics manage nausea or vomiting and likewise don’t modify RA pathology. In practice, initiating DMARD therapy early and maintaining it, often with a treat-to-target approach, is key to altering the condition’s progression, whereas symptom-relief medications may improve comfort but don’t change long-term joint outcomes.

DMARDs are the class that can influence the course of rheumatoid arthritis by actually slowing or halting the underlying inflammatory process that drives joint damage. They target the immune mechanisms that cause synovitis and erosion, so using them can reduce radiographic progression, preserve joint function, and improve long-term outcomes. Conventional options like methotrexate, sulfasalazine, hydroxychloroquine, and leflunomide, as well as biologic agents that inhibit TNF or other inflammatory pathways, illustrate how this class changes the disease trajectory rather than just masking symptoms.

Other options don’t alter the disease course. Antivirals treat viral infections and have no direct effect on the autoimmune inflammation of RA. Decongestants are used for nasal symptoms and do not impact the inflammatory process in joints. Emetics manage nausea or vomiting and likewise don’t modify RA pathology.

In practice, initiating DMARD therapy early and maintaining it, often with a treat-to-target approach, is key to altering the condition’s progression, whereas symptom-relief medications may improve comfort but don’t change long-term joint outcomes.